Guggenheim analyst Eddie Hickman lowered the firm’s price target on ProMIS Neurosciences (PMN) to $5 from $6 and keeps a Buy rating on the shares. ProMIS Neurosciences’ Alzheimer’s candidate, PMN310, is rapidly advancing toward key clinical milestones, which keeps the company on track for two pivotal data readouts in 2026, the analyst tells investors following the company’s Q3 report.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN:
- Promising Advancements in Alzheimer’s Research and Strong Financial Position Support Buy Rating for ProMIS Neurosciences
- ProMIS Neurosciences Reports Increased R&D Costs and Net Loss
- ProMIS Neurosciences reports Q3 EPS (24c) vs 31c last year
- PMN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ProMIS Neurosciences Advances Alzheimer’s Study with PMN310